Angelini Ventures
A new era for European healthcare: Angelini Ventures partners with the EIB to transform healthcare innovation
Angelini Ventures is proud to announce a landmark partnership with the European Investment Bank (EIB), marking the first collaboration between the EIB and a healthcare corporate venture capital fund in Europe. This €150 million agreement represents a shared commitment to strengthening Europe's position as a global leader in biotechnology, medtech, and digital health innovation.
Under this partnership, Angelini Ventures and the EIB will each invest €75 million over the next six years, co-investing in a total of seven to ten European startups developing breakthrough solutions that will improve patients' lives and drive meaningful impact across the healthcare sector.
The signing of this agreement took place at Angelini Ventures' headquarters in Rome, bringing together key leaders from both organizations: Sergio Marullo di Condojanni (CEO, Angelini Industries), Paolo Di Giorgio (CEO, Angelini Ventures), Stefano Marzario (Senior Officer, EIB), and virtually, Gelsomina Vigliotti (Vice-President, EIB) and Daniela Saccone (Senior Legal Officer, EIB).
This important agreement with the EIB enables us to bring our group's commitment to innovation through venture capital to a European strategic context. Being chosen by the EIB for an ambitious project aiming to consolidate Europe's role in innovation and health is an opportunity to work towards the common goal of turning researchers' excellent ideas into products and services with a positive impact on people's lives and the economic development of European countries.
Prof. Sergio Marullo di Condojanni,
This development path is essential to accelerating market access for talent and innovative projects, facilitating strategic partnerships in health and offering scaling opportunities. These elements are fundamental to speeding up growth and creating value in the healthcare and biotechnology sector, promoting European innovation, competitiveness and social impact on an international level. The agreement with the EIB is a key step in strengthening our international presence and global vision.
Paolo Di Giorgio,
As a first milestone of this partnership, Angelini Ventures and the EIB are co-investing in the second financing round of Adcytherix, a French biopharmaceutical company developing innovative Antibody-Drug Conjugates for precision medicine.
This collaboration is aligned with TechEU, the EIB Group's €70 billion investment programme designed to strengthen technological innovation and leadership across Europe, with the ambition to mobilize €250 billion of investment in the real economy by 2027.
Discover more about this partnership by reading the full press releases available below: